Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476311 | 0.81 | SMYD3 (0.44) | ADRB2ADRB1SMYD3 | |
| SCHEMBL17476273 | 0.81 | SMYD3 (0.44) | ADRB2ADRB1SMYD3 | |
| SCHEMBL17476275 | 0.81 | SMYD3 (0.44) | ADRB2ADRB1SMYD3 | |
| Hydrochloric Acid SCHEMBL17476307 | 0.80 | ADRB2 (0.46) | ADRB2ADRB1SMYD3 | |
| SCHEMBL18227271 | 0.78 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL18239919 | 0.75 | ADRB2 (0.43) | ADRB2ADRB1 | |
| SCHEMBL17476264 | 0.75 | SMYD3 (0.47) | SMYD3 | |
| SCHEMBL17476277 | 0.75 | ADRB2 (0.49) | ADRB2ADRB1SMYD2 | |
| SCHEMBL13494723 | 0.74 | ADRB1 (0.46) | ADRB2ADRB1 | |
| SCHEMBL22864201 | 0.74 | ADRB1 (0.65) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031838-A1 | SMYD2 INHIBITORS | SMYD2, SMYD3, NSD1 | ADRB2 4561/4885ADRB1 4623/4885SMYD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.